RRM1 and non-small cell lung carcinoma: The prospective study assessed if chemotherapy selection based on in situ excision repair cross-completion group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) protein levels would improve survival in patients with advanced NSCLC [7].